Treatment of gastrointestinal stromal tumours in paediatric and young adult patients with sunitinib: a multicentre case series.

ABSTRACT:

Background

Gastrointestinal stromal tumours (GIST) are rarely encountered mesenchymal tumours of the gastrointestinal tract (1.5 people per 100,000/year) that are even more rarely seen in paediatric patients (1-2% of all cases). The standard treatment for advanced adult GIST is imatinib with sunitinib as a second-line option. Although the efficacy and tolerability of sunitinib in adults with GIST has been established, little is known of the profile of sunitinib in paediatric/young adult patients with GIST given the rarity of this disease.

Methods

Paediatric/young adult patients aged up to 21 years with diagnosis of GIST who were treated with sunitinib were identified from retrospective records from three centres in Europe and the US. Most patients commenced sunitinib in a 6-

SUBMITTER: Rutkowski P 

PROVIDER: S-EPMC5674814 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature